P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB

• Maria-Victoria Mateos,
• Nizar J Bahlis,
• Andrew Spencer,
• Rayan Kaedbey,
• Paula Rodríguez-Otero,
• Simon Harrison,
• Chihunt Wong,
• Grant Goodman,
• Rin Nakamura,
• Voleak Choeurng,
• James Cooper,
• Suzanne Trudel

Affiliations

Maria-Victoria Mateos

1 Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain

Nizar J Bahlis

2 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada

Andrew Spencer

3 Alfred Health-Monash University, Melbourne, VIC, Australia

Rayan Kaedbey

4 Jewish General Hospital, McGill University, Montreal, QC, Canada

Paula Rodríguez-Otero

5 Clínica Universidad de Navarra, Pamplona, Spain

Simon Harrison

6 Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University, and The Royal Melbourne Hospital, Melbourne, VIC, Australia

Chihunt Wong

7 Genentech, Inc., South San Francisco, CA, United States

Grant Goodman

7 Genentech, Inc., South San Francisco, CA, United States

Rin Nakamura

7 Genentech, Inc., South San Francisco, CA, United States

Voleak Choeurng

7 Genentech, Inc., South San Francisco, CA, United States

James Cooper

7 Genentech, Inc., South San Francisco, CA, United States

Suzanne Trudel

8 Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada